摘要:
The invention relates to novel trans N-{4-{2-[4-(2,3-dichlorophenyl)-piperazine-l-il]-ethyl}- cyclohexylamine dihydrochloride monohydrate and a process for the preparation of the trans N- {4- {2-[4-(2,3-dichlorophenyl)-piperazine-l -il]-ethyl}-cyclohexylamine dihydrochloride monohydrate, said process comprising the steps a) reacting trans 2-{l-[4-(N-tert-butoxycarbonyl)amino]- cyclohexyl} -acetic acid ester with sodium borohydride and aluminium trichloride to give trans 2-{l-[4-(N-tert-butoxycarbonyl)-amino]-cyclohexyl}-ethanol; b) reacting trans 2-{l-[4-(N-tert-butoxycarbonyl)-amino]cyclohexyl}-ethanol obtained with methanesulfonic acid chloride in the presence of an acid binding agent to give trans 2-{l-[4- (N-tert-butoxycarbonyl)-amino] -cyclohexyl} -ethyl methanesulfonate; c) reacting trans 2-{l-[4-(N-tert-butoxycarbonyl)-amino]-cyclohexyl}-ethyl methanesulfonate obtained with 2,3-dichlorophenyl-piperazine in the presence of an acid binding agent to give trans 2-{l-[4-(N-tert-butoxycarbonyl)-amino]-cyclohexyl}-carbamic acid tert-butylester; d) heating trans 2-{l-[4-(N-tert-butoxycarbonyl)-amino]-cyclohexyl}-carbamic acid tert- butylester obtained to a temperature between 40-100°C in a mixture of aqueous hydrochloric acid/methanol to give trans N-{4-{2-[4-(2,3-dichlorophenyl)piperazine-l-il]-ethyl}- cyclohexylamine dihydrochloride monohydrate.
摘要:
The present invention relates to new D 3 and D 2 dopamine receptor subtype preferring ligands of formula (I): wherein R 1 and R 2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R 1 and R 2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
摘要:
New mGluRl and mGluR5 receptor subtype preferring ligands of formula: (I) and/or salts and/or hydrates and/or solvates thereof, to the processes and intermediates for their preparation, to pharmaceutical compositions containing these compounds and to their use in therapy and/or prevention of a condition which requires modulation of mGluRl and mGluR5 receptors.FORMULE (I) wherein Ar 1 represents an optionally substituted phenyl or heteroaryl group; Ar 2 represents a substituted phenyl or an optionally substituted heteroaryl group; R 1 , R 2 , R 3 and R 4 represent independently a substituent selected from hydrogen, halogen, cyano, alkyl, alkoxy, hydroxy, trifluoromethyl, amino, alkylamino, dialkylamino, aminomethyl, alkylaminomethyl, dialkylaminomethyl
摘要翻译:新的mGluR1和mGluR5受体亚型优选式(I)的配体和/或其盐和/或水合物和/或溶剂化物,其制备方法和中间体,含有这些化合物的药物组合物及其在治疗和 /或预防需要调节mGluR1和mGluR5受体的病症。其中Ar 1表示任选取代的苯基或杂芳基; Ar 2表示取代的苯基或任选取代的杂芳基; R1,R2,R3和R4独立地表示选自氢,卤素,氰基,烷基,烷氧基,羟基,三氟甲基,氨基,烷基氨基,二烷基氨基,氨基甲基,烷基氨基甲基,二烷基氨基甲基
摘要:
The invention relates to a process for the preparation of the trans N-{ 4-{2-[4-(2,3- dichlorophenyl)-piperazine-1-yl]-ethyl}-cyclohexyl}-carbamide derivatives of formula (I) by reacting the compound of formula (III) with a carbamoylchloride of formula (II) which comprises carrying out the reaction in a mixture of a solvent and concentrated aqueous solution of an alkali hydroxide at a temperature between 40-100 °C in the presence of a phase transfer catalyst, separating the phases and washing the organic layer then removing the solvent and drying the compound of formula (I) obtained until its weight is constant.
摘要:
The present invention relates to new D 3 dopamine receptor subtype selectice ligands of formula (I) to pharmacological compositions containing the same and to their us in therapy and/or prevention of psychoses ( e.g. schizophrenia, schizo-affective disorders, etc ), drug ( e.g. alcohol, cocaine and nicotine, opioids etc. ) abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, amnesia, eating disorders ( e.g. bulimia nervosa, etc. ), attention deficit disorders, hyperactivity disorders in children, psychotic depression, mania, paranoid and delusional disorders, dyskinetic disorders (e.g. Parkinson's diseases, neuroleptic induced Parkinson's desases, tardive dyskinesias) anxiety, sexual dysfunction, sleep disorders, emesis, aggression, autism, pain ophthalmological diseases ( e.g. glaucoma etc. ).
摘要:
The present invention relates to new D 3 dopamine receptor subtype selective ligands of Formula (I), wherein R 1 , R 2 and R 3 independently represent substituents selected from hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, hydroxy, trifluoromethyl, C 1-6 alkylsulfonyloxy, trifluoromethanesulfonyloxy, optionally substituted C 1-6 alkanoyloxy, amino, aminoalkyl, carboxy, aminocarbonyl, N-hydroxycarbamimidoyl, carbamimidoyl, hydroxycarbamoyl, thiocarbamoyl, sulfamoyl, optionally substituted phenyl or naphthyl, optionally substituted mono or bicyclic heterocyclic group, two adjacent groups of R 1 , R 2 and R 3 may combine to form an optionally substituted fused mono or bicyclic heterocyclic group, with the exception of compounds wherein a) R 1 = R 2 = R 3 = H, b) R 1 = R 2 = H and R 3 = C 1-6 alkoxy in the position 2 or R 3 is in the position 4 of the piperazinylphenyl moiety, c) R¿1 ?= H and R 2 = R 3 = C 1-6 alkoxy; Q represents an optionally substituted C 1-6 alkyl, C 1-6 alkenyl, phenyl or heteroaryl group.
摘要翻译:本发明涉及式(I)的新的D3多巴胺受体亚型选择性配体,其中R 1,R 2和R 3独立地表示选自氢,卤素,C 1-6烷基,C 1-6烷氧基,氰基,羟基,三氟甲基,C 1-6烷基磺酰氧基 ,三氟甲磺酰氧基,任选取代的C 1-6烷酰氧基,氨基,氨基烷基,羧基,氨基羰基,N-羟基甲脒基,氨基甲酰基,氨基甲酰基,硫代氨基甲酰基,氨磺酰基,任选取代的苯基或萘基,任选取代的单或双环杂环基, 并且R 3可以结合形成任选取代的稠合单或双环杂环基,除了其中a)R 1 = R 2 = R 3 = H,b)R 1 = R 2 = H和R 3 = C 1-6烷氧基在位置2或 R3在哌嗪基苯基部分的位置4,c)R1 = H,R2 = R3 = C1-6烷氧基; Q表示任选取代的C 1-6烷基,C 1-6烯基,苯基或杂芳基。
摘要:
The invention relates to a process for the preparation of an antipsoriatic pharmaceutical composition containing 17,18-dehydroapovincaminol 3',4',5'-trimethoxybenzoate or its pharmaceutically acceptable acid addition salts, which comprises dissolving one equivalent of 17,18-dehydroapovincaminol 3',4',5'-trimethoxybenzoate or its pharmaceutically acceptable acid addition salt in 1.1 to 50, preferably 5 to 20, equivalents of an organic acid containing no basic group and being soluble in water or in a water-miscible monovalent or polyvalent alcohol or in a mixture thereof, or in a solution prepared from the organic acid with water or with a water-miscible monovalent or polyvalent alcohol or with a mixture thereof, and a) formulating the solution to a pharmaceutical composition as such or, if desired, together with therapeutically active agents showing no synergism with the active ingredient and/or with pharmaceutical auxiliary materials (additives), or b) diluting the solution with 5 to 50 parts by weight of water and formulating the thus-obtained gel, containing the active ingredient in a homogenous molecular distribution, as such or together with therapeutically active agents showing no synergism with the active ingredient and/or with a pharmaceutically acceptable auxiliary materials to a pharmaceutical composition.
摘要:
The invention relates to a new process for the preparation of compounds of general formula (I) wherein R 1 and R 2 represent independently hydrogen or C 1-6 alkyl with straight or branched chain optionally substituted with aryl group; or C 2-7 alkenyl containing 1-3 double bonds; or monocyclic, bicyclic or tricyclic aryl optionally substituted with one or more C1-6 alkoxy, trifiuoro-C 1-6 alkoxy, C 1-6 -alkoxycarbonil, C 1-6 alkanoyl, aryl, C 1-6 alkylthio, halogen or cyano; or optionally substituted monocyclic, bicyclic or tricyclic C 3-14 cycloalkyl group; R 1 and R 2 together with the adjacent nitrogen form a saturated or unsaturated optionally substituted monocyclic or bicyclic heterocyclic ring which may contain further heteroatoms selected from oxygen, nitrogen, or sulphur atoms and hydrochloric acid salts and/or hydrates and/or solvates thereof, by dissolving or suspending trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-il]-ethyl}-cyclohexylamine of formula (III) or a salt or a hydrate or a solvate thereof in an inert solvent in the presence of a base then adding a carbonic acid derivative of general formula (VI) wherein R is alkyl with C 1-6 straight or branched chain, partially or fully halogenated C 1-2 alkyl or phenyl, Z is -O-R or -X, wherein R is as described above, X is halogen, and reacting the compound of general formula (IV) obtained wherein R is as described above, in situ or, optionally in isolated state with an amine of general formula (V) wherein R 1 and R 2 are as described above to obtain the compound of general formula (I) and then optionally forming the hydrochloride salts and/or hydrates and/or solvates thereof.
摘要:
The present invention relates to new mGluR5 receptor subtype preferring ligands of formula (I): (I) wherein R 1 and R 2 represent independently a substituent selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl and cyano; X is a CHR6 group or O; R 3 represents an alkyl substituent, R 4 and/or R 5 represent hydrogen, R 6 is hydrogen or alkyl, or R 3 and R 4 with the intermediate two carbon atoms together form a cyclohexane or cyclopentane ring and/or R 5 and R 6 together form a bond; Y is an optionally substituted phenyl or heterocyclyl, and/or enantiomers and/or racemates and/or diastereomers and/or geometric isomers and/or salts and/or hydrates and/or solvates thereof, to the process for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of pathological conditions which require the modulation of niGluR5 receptor such as neurological disorders, psychiatric disorders, acute and chronic pain and neuromuscular dysfunctions of the lower urinary tract.
摘要:
A process for preparing cabergoline (I) from ergoline-8β-carboxylic acid ester (XIII) comprising the following steps. (XIII), (XVI), (XVII), (XVIII), (XIX), (I). The present case also relates to the intermediates (XVI), (XVII), (XVIII) and (XIX) as well as the polymorphic amorphous form of Cabergoline (I) and the production thereof.